Compare Gilead Sciences, Inc. (GILD) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Neurocrine Biosciences Inc — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while Neurocrine Biosciences Inc trades at $142.36 (market cap $14.36B). The key difference: Gilead Sciences, Inc. is far larger — about 12.7× Neurocrine Biosciences Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GILD | NBIX | |
|---|---|---|
Market Cap | $182.40B | $14.36B |
Volume | 4,469,821 | 1,237,180 |
Sector | Health | Health |
52-Week High | $155.80 | $185.50 |
52-Week Low | $116.74 | $123.10 |
Typical Hold Time | 111 Days | 23 Days |
Enterprise Value | $205.46B | $14.37B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
